Nexterone (Amiodarone In Dextrose,Iso-Osm) Patent Expiration, LOE Window & CMS Spending
Nexterone (Amiodarone In Dextrose,Iso-Osm) by Baxter Healthcare: FDA Orange Book LOE 2033-02-27, 9 AB generics, $503K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Baxter Healthcare |
| FDA Application & Pathway | N022325 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-02-27 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $503K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $503K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.